iBio, Inc. (IBIO)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.45 USD
-0.06
(-3.974%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.50 +0.05 (3.448%) ⇧ (July 13, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:07 a.m. EDT
The immediate outlook is severely clouded by a relentless multi-year price collapse, with five consecutive years of negative annual returns ending in a steep 62.5% drop last year. While the company recently secured regulatory clearance for a Phase 1 trial and raised capital, the market has priced in a catastrophic failure of the business model, evidenced by a 99.98% cumulative loss over the last nine years and negative operating margins of nearly 97%. The balance sheet, while currently showing low debt relative to equity, is propped up by minimal cash reserves against significant free cash outflows, creating a precarious runway for a biotech firm with no earnings. There is no dividend to provide income, and the statistical models offer no short-term relief, reflecting the deep uncertainty surrounding the upcoming clinical data. Investors should view this as a high-risk speculative bet rather than an investment, given the structural deterioration and the sheer magnitude of past losses. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.065829 |
| AutoETS | 0.073691 |
| AutoTheta | 0.184979 |
| AutoARIMA | 0.359413 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.654 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.999 |
| Revenue per Share | 0.004 |
| Market Cap | 72,033,912 |
| Forward P/E | -4.68 |
| Beta | 1.27 |
| Website | https://ibioinc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.96103895 |
| Address1 | 11,750 Sorrento Valley Road |
| Address2 | Suite 200 |
| All Time High | 30,300.0 |
| All Time Low | 0.56 |
| Ask | 1.86 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,336,660 |
| Average Daily Volume3 Month | 962,762 |
| Average Volume | 962,762 |
| Average Volume10Days | 1,336,660 |
| Beta | 1.271 |
| Bid | 1.1 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 2.245 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.45 |
| Current Ratio | 11.877 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.555 |
| Day Low | 1.445 |
| Debt To Equity | 2.999 |
| Display Name | iBio |
| Dividend Date | 1,528,675,200 |
| Earnings Timestamp End | 1,758,542,400 |
| Earnings Timestamp Start | 1,758,193,140 |
| Ebitda | -28,271,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.015 |
| Enterprise To Revenue | -1.46 |
| Enterprise Value | -438,086 |
| Eps Current Year | -0.33143 |
| Eps Forward | -0.31 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6818 |
| Fifty Day Average Change | -0.23179996 |
| Fifty Day Average Change Percent | -0.1378285 |
| Fifty Two Week Change Percent | 96.1039 |
| Fifty Two Week High | 3.82 |
| Fifty Two Week High Change | -2.37 |
| Fifty Two Week High Change Percent | -0.62041885 |
| Fifty Two Week Low | 0.56 |
| Fifty Two Week Low Change | 0.89000005 |
| Fifty Two Week Low Change Percent | 1.5892857 |
| Fifty Two Week Range | 0.56 - 3.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,219,152,600,000 |
| Float Shares | 45,473,768 |
| Forward Eps | -0.31 |
| Forward P E | -4.6774197 |
| Free Cashflow | -15,243,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 300,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01714 |
| Held Percent Institutions | 0.48646998 |
| Implied Shares Outstanding | 49,678,561 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-03-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,701,216,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
| Long Name | iBio, Inc. |
| Market | us_market |
| Market Cap | 72,033,912 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_33000 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -27,606,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 75,014,627 |
| Number Of Analyst Opinions | 8 |
| Open | 1.48 |
| Operating Cashflow | -21,605,000 |
| Operating Margins | -96.53 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 979 446 0027 |
| Post Market Change | 0.049999952 |
| Post Market Change Percent | 3.4482725 |
| Post Market Price | 1.5 |
| Post Market Time | 1,783,986,084 |
| Previous Close | 1.51 |
| Price Eps Current Year | -4.3749814 |
| Price Hint | 4 |
| Price To Book | 0.6458798 |
| Price To Sales Trailing12 Months | 240.11304 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.5 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -3.97351 |
| Regular Market Day High | 1.555 |
| Regular Market Day Low | 1.445 |
| Regular Market Day Range | 1.445 - 1.555 |
| Regular Market Open | 1.48 |
| Regular Market Previous Close | 1.51 |
| Regular Market Price | 1.45 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,070,164 |
| Return On Assets | -0.34495997 |
| Return On Equity | -0.62092996 |
| Revenue Per Share | 0.004 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 49,678,561 |
| Shares Percent Shares Out | 0.0945 |
| Shares Short | 4,694,085 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,760,082 |
| Short Name | iBio, Inc. |
| Short Percent Of Float | 0.095 |
| Short Ratio | 5.49 |
| Source Interval | 15 |
| State | CA |
| Symbol | IBIO |
| Target High Price | 7.0 |
| Target Low Price | 4.2 |
| Target Mean Price | 5.4 |
| Target Median Price | 5.0 |
| Total Cash | 74,797,000 |
| Total Cash Per Share | 1.506 |
| Total Debt | 2,325,000 |
| Total Revenue | 300,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.77925 |
| Two Hundred Day Average Change | -0.32924998 |
| Two Hundred Day Average Change Percent | -0.18504986 |
| Type Disp | Equity |
| Volume | 1,070,164 |
| Website | https://ibioinc.com |
| Zip | 92,121 |